- Double Mastectomy May Offer No Survival Benefit to Women With Breast Cancer
- Toxic Lead Found in Cinnamon Product, FDA Says
- Certain Abbott Blood Sugar Monitors May Give Incorrect Readings
- Athletes Can Expect High Ozone, Pollen Counts for Paris Olympics
- Fake Oxycontin Pills Widespread and Potentially Deadly: Report
- Shingles Vaccine Could Lower Dementia Risk
- Your Odds for Accidental Gun Death Rise Greatly in Certain States
- Kids From Poorer Families Less Likely to Survive Cancer
- Tough Workouts Won’t Trigger Cardiac Arrest in Folks With Long QT Syndrome
- At-Home Colon Cancer Test Can Save Lives
Northera Approved For Rare Blood Pressure Condition
![](https://ladylively.com/wp-content/uploads/2013/08/public-health10-300x336.jpg)
Northera (droxidopa) has been approved by the U.S. Food and Drug Administration to treat a rare, chronic condition characterized by a sudden drop in blood pressure when a person stands.
Neurogenic orthostatic hypotension (NOH) is most often associated with Parkinson’s disease and other neurologic disorders. Symptoms may include dizziness, lightheadedness, blurred vision, fatigue and fainting, the FDA said in a news release.
Granted accelerated approval to treat a rare condition, the drug will have a boxed label warning that it could cause an unhealthy rise in blood pressure while a person is lying down. This potential side effect could lead to a stroke, the agency said, warning that Northera users should be monitored carefully.
Other less serious side effects could include headache, dizziness, nausea, high blood pressure and fatigue, the FDA said.
Northera is produced by Chelsea Therapeutics, based in Charlotte, N.C.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.